Nebenwirkungen · Xgeva
XGEVA 120 mg solution for injection XGEVA 120 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-124656 · Präparat HOS-095905
A non-randomised, retrospective, observational study in 2,877 patients with cancer treated with XGEVA or zoledronic acid in Sweden, Denmark, and Norway showed that 5-year incidence proportions of medically confirmed ONJ were 5.7% (95% CI: 4.4, 7.3; median follow-up time of 20 months [range 0.2 - 60]) in a cohort of patients receiving XGEVA and 1.4% (95% CI: 0.8, 2.3; median follow-up time of 13 months [range 0.1 - 60]) in a separate cohort of patients receiving zoledronic acid. Five-year incidence proportion of ONJ in patients switching from zoledronic acid to XGEVA was 6.6% (95% CI: 4.2, 10.0; median follow-up time of 13 months [range 0.2 - 60]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-30T11:39:12Z · SHA-256 128fc1cc30bb902fd35b573513956c486b321d921f1c9f82cbb86938b613ea4c · Passage c42ae72eca68fd5f89c02a7ecff104364b851ee18618cddbd0c6ed54027f625a · Zeichen 9229–9884 im Abschnitt